{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-024297","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.918078+00:00","generated_at":"2026-05-31T13:44:00.038289+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M","bullets":["Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.","GAAP net loss $4.5M ($0.09 loss per share) vs net income $2.1M ($0.05 EPS) in Q2 2023.","Non-GAAP adjusted net loss $2.5M ($0.05 loss per share) vs adjusted net income $4.6M ($0.10 EPS).","Cash & equivalents $96.8M at June 30, 2024; net cash from ops $1.0M in Q2.","FY2024 guidance: net product revenue $183-190M, net income $12-15M; Q3 net product revenue $50-53M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-024297","json":"https://secwatch.observer/filing/0001437749-24-024297.json","markdown":"https://secwatch.observer/filing/0001437749-24-024297.md","text":"https://secwatch.observer/filing/0001437749-24-024297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924024297/0001437749-24-024297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924024297/pbyi20240731_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:44:00.038289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}